A detailed history of China Universal Asset Management Co., Ltd. transactions in Scholar Rock Holding Corp stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 15,393 shares of SRRK stock, worth $701,305. This represents 0.01% of its overall portfolio holdings.

Number of Shares
15,393
Previous 9,370 64.28%
Holding current value
$701,305
Previous $78,000 57.69%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$7.63 - $9.71 $45,955 - $58,483
6,023 Added 64.28%
15,393 $123,000
Q2 2024

Jul 19, 2024

SELL
$7.84 - $16.79 $35,264 - $75,521
-4,498 Reduced 32.43%
9,370 $78,000
Q1 2024

Apr 29, 2024

BUY
$13.2 - $17.76 $72,890 - $98,070
5,522 Added 66.16%
13,868 $246,000
Q4 2023

May 21, 2024

SELL
$6.52 - $20.32 $36,003 - $112,207
-5,522 Reduced 39.82%
8,346 $156,000
Q4 2023

Jan 23, 2024

BUY
$6.52 - $20.32 $45,020 - $140,309
6,905 Added 479.18%
8,346 $157,000
Q3 2023

May 21, 2024

BUY
$6.02 - $7.76 $4,388 - $5,657
729 Added 102.39%
1,441 $10,000
Q3 2023

Oct 30, 2023

BUY
$6.02 - $7.76 $4,388 - $5,657
729 Added 102.39%
1,441 $10,000
Q2 2023

May 21, 2024

BUY
$5.79 - $9.11 $69 - $109
12 Added 1.71%
712 $5,000
Q2 2023

Jul 27, 2023

BUY
$5.79 - $9.11 $69 - $109
12 Added 1.71%
712 $5,000
Q1 2023

May 21, 2024

BUY
$7.36 - $12.72 $1,288 - $2,226
175 Added 33.33%
700 $5,000
Q1 2023

Apr 27, 2023

BUY
$7.36 - $12.72 $1,288 - $2,226
175 Added 33.33%
700 $6,000
Q4 2022

May 21, 2024

SELL
$7.02 - $9.76 $93,667 - $130,227
-13,343 Reduced 96.21%
525 $4,000
Q4 2022

Jan 31, 2023

BUY
$7.02 - $9.76 $294 - $409
42 Added 8.7%
525 $5,000
Q3 2022

Oct 21, 2022

BUY
$5.33 - $11.3 $2,574 - $5,457
483 New
483 $3,000

Others Institutions Holding SRRK

About Scholar Rock Holding Corp


  • Ticker SRRK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,640,600
  • Market Cap $2.35B
  • Description
  • Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clini...
More about SRRK
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.